-
Antengene and MSD Collaborate on Global Clinical Study for ATG-037
•
China-based Antengene Corporation Limited (HKG: 6996) has announced a global clinical collaboration with Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) to conduct a multicenter, open-label, Phase I dose-finding study for ATG-037 as a monotherapy and in combination with MSD’s anti-PD-1 therapy, Keytruda (pembrolizumab). The targeted indication is locally advanced…
-
IASO Biotherapeutics Receives FDA Approval for CT103A IND Application
•
China-based IASO Biotherapeutics has announced approval from the US FDA for an Investigational New Drug (IND) application for its BCMA-targeted chimeric antigen receptor (CAR) T cell therapy CT103A (equecabtagene autoleucel). The therapy will be assessed in US-based clinical trials for relapsed/refractory multiple myeloma (r/r MM). Drug Profile and DevelopmentEquecabtagene autoleucel…
-
Shenzhen Würzburg Dynamics Raises RMB 100 Million in Series A Financing Round
•
China-based Shenzhen Würzburg Dynamics has reportedly raised RMB 100 million (USD 14.36 million) in a Series A financing round. The funding was led by 3E Bioventures Capital, with contributions from Tzitzit Asset and Fosun Health Capital. The proceeds will be used for research and development and market construction for multiple…
-
AcornMed Raises RMB 200 Million in Series B Financing Led by Yikai Venture Capital
•
AcornMed, a tumor precision medicine specialist based in Beijing, has reportedly raised RMB 200 million (USD 28.7 million) in a Series B financing round led by Yikai Venture Capital. Other investors included Lichen Investment, Qingdao Hongteng, and Wushi Capital. The proceeds will be used for research and development of tumor…
-
CSPC’s NBL-020 Receives FDA IND Approval for Advanced Solid Tumors
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving Investigational New Drug (IND) approval from the US FDA for its antibody-drug NBL-020. The targeted indication is advanced solid tumors, marking a significant step forward in the development of this innovative therapy. Drug Profile and Mechanism of ActionNBL-020 is an…
-
Jiangsu Chia Tai Tianqing’s TQB2102m Gains NMPA Clinical Approval
•
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd’s (CTTQ) Category 1 biologic product TQB2102m, an HER2 targeted antibody drug conjugate (ADC), has obtained clinical approval from the National Medical Products Administration (NMPA). The targeted indication is advanced malignant tumors, with no similar product currently approved for marketing anywhere in the world.…
-
WuXi XDC Partners with GeneQuantum for ADC Development
•
China-based WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced a partnership with compatriot firm GeneQuantum Healthcare (Suzhou) Co., Ltd in relation to antibody-drug conjugate (ADC) development. The collaboration aims to advance the development and…
-
Hengrui Pharmaceuticals Receives New Approval for Remimazolam Tosylate
•
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced one new supplementary approval for its gamma-aminobutyric acid type A (GABAA) receptor antagonist remimazolam tosylate. The approval, with the indication being sedation and anesthesia during non-tracheal intubation surgery / operation, marks the drug’s fourth market approval. Previous Approvals and Clinical StudiesRemimazolam tosylate…
-
Neurophth Partners with Apellis for Gene Therapy Development in AMD
•
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with US firm Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) to develop a gene therapy based on the complement regulation mechanism for geographic atrophy (GA) / dry age-related macular degeneration (dAMD). Financial details of the partnership were not disclosed. Apellis’…
-
Jing Medicine’s HJM-353 Gains Clinical Trial Approvals in US and China
•
China-based Jing Medicine Technology (Shanghai) Co., Ltd’s HJM-353 has obtained clinical trial approvals in the US and China. The investigational embryonic ectoderm development (EED) inhibitor is expected to enter a Phase I clinical study for advanced blood cancer and solid tumors. Mechanism of Action and DevelopmentPolycomb repressive complex 2 (PRC2)…
-
Jiangsu Vcare PharmaTech Raises RMB 200 Million in Series B Financing Round
•
China-based Jiangsu Vcare PharmaTech Co. Ltd has reportedly raised over RMB 200 million (USD 28.67 million) in a Series B financing round. The round was led by Changjiang Venture Capital, with additional investments from Hongcheng Investment, Huadian Investment, Yangtze Investment, and SDIC. The proceeds will be used for clinical development…
-
MindRank AI Receives FDA Approval for MDR-001 Clinical Study in Obesity
•
Hangzhou-based artificial intelligence (AI)-driven biotech MindRank AI has announced obtaining approval from the US FDA to conduct a clinical study for its oral, small molecule GLP-1 receptor agonist (RA) drug MDR-001 in obesity. This marks a significant milestone in the development of MDR-001, positioning MindRank AI to advance its innovative…
-
Hangzhou Biotest Receives FDA EUA for COVID-19 Antigen Self-Testing Reagent
•
China-based Hangzhou Biotest Biotech Co., Ltd has announced receiving an Emergency Use Authorization (EUA) from the US FDA for its novel coronavirus antigen self-testing reagent. This authorization marks a significant step in expanding the availability of COVID-19 testing options in the US market. Product Details and UsageThe COVID-19 antigen self-testing…
-
Junshi Biosciences Licenses PD-1 Inhibitor Tuoyi to Hikma MENA FZE
•
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a licensing agreement with UK-headquartered Hikma MENA FZE, granting the latter exclusive development and commercialization rights to its programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) in Jordan, Saudi Arabia, the United Arab Emirates, Qatar, Morocco, and Egypt, among a total of 20…
-
Shanghai Pharmaceuticals Secures Exclusive Rights for Shionogi’s Ensitrelvir in China
•
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has announced an import and distribution agreement with Japan-based Shionogi & Co., Ltd, becoming the exclusive importer and agent of the latter’s oral COVID-19 therapy ensitrelvir in mainland China. The two-year deal also includes a collaboration on innovative and generic drugs. Financial details of…
-
WHO Approves Sinovac’s CoronaVac for Children Aged 3 and Above
•
The World Health Organization (WHO) has lowered the age limit for Sinovac Biotech Ltd’s (NASDAQ: SVA) COVID-19 vaccine, CoronaVac, to three years old. This makes it the first vaccine on the WHO’s Emergency Use List (EUL) to be approved for such a young age group and the only one recommended…
-
Fosun Pharma’s Avatrombopag Receives NMPA Review for Chronic ITP Indication
•
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that another indication approval filing for its avatrombopag has been accepted for review by the National Medical Products Administration (NMPA). The targeted indication is chronic immune thrombocytopenia (ITP). Drug Profile and DevelopmentAvatrombopag is a thrombopoietin (TPO) receptor…
-
Nanjing Pharmaceutical to Acquire Majority Stakes in Three Jiangsu Subsidiaries
•
China-based Shanghai-listed Nanjing Pharmaceutical Co., Ltd (SHA: 600713) is set to acquire a respective 55%, 55%, and 100% stake in three subsidiaries of compatriot firm Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. The deals entail a consideration of RMB 148 million (USD 21.2 million). The subsidiaries involved are Suzhou Tianqing…
-
MSD and Kelun Biotech Ink Record-Breaking ADC Deal
•
Merck, Sharp & Dohme (MSD, NYSE: MRK) has set a new benchmark for the largest out-licensing deal between a multinational and a China-based firm. The US giant has returned to sign its third deal of this year with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, securing development, manufacturing, and commercialization rights to…
-
Shyndec’s Generic Cytosar-U Gains Marketing Approval in China
•
China-based Shanghai Shyndec Pharmaceutical Co., Ltd (SHA: 600420) has announced that its generic version of Pfizer’s (NYSE: PFE) Cytosar-U (cytarabine) has obtained marketing approval in China. This marks the first generic to pass the generic quality consistency evaluation among similar products in the country. Product Profile and Market ContextCytarabine for…
